
Rezafungin May Provide Early Treatment Benefit in Candidemia, Invasive Candidiasis
A comparison of rezafungin and caspofungin for the treatment of candidemia and invasive candidiasis found that rezafungin may offer an early treatment benefit with its front-loaded dosing regimen. Study findings published in The Lancet Infectious Diseases showed that rezafungin was noninferior to caspofungin in terms of all-cause mortality and had higher rates of mycologic eradication….